Becton, Dickinson and Company company logo

# RNN 2nd Gen Model Becton, Dickinson and Company Surgical & medical instruments

Prediction models:
Subscribe >> Deal exit on
June 24, 2019
Deal entry on
June 24, 2019
34.99%Expected margin
50.00% successful of 2 deals
$ 234.16 Last close price
at 14-jun-2019

BDX

Model's trade recommendations No return for period yet

-2.22% Annual return

$61.29B Market Cap

β 1.15  

BDX

Model (following trade recommendations)

BDX

Underlying stock

S&P 500

Index
Return for period
2.54%
1.78%
52wk return
0.86%
16.82%
52wk Range
209.85—264.38
2000.54—2399.63
Sortino ratio -0.63
Sharpe ratio -0.63
Norm. RMSE 31.01%
Downside risk 3.94%
Volatility 0.00%
  • 3.00 (1.30%) Div (Yield)
  • STRONG BUY Analysts consensus recommendation

Becton, Dickinson & Company is a global medical technology company that is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. BD leads in patient and health care worker safety and the technologies that enable medical research and clinical laboratories. The company provides innovative solutions that help advance medical research and genomics, enhance the diagnosis of infectious disease and cancer, improve medication management, promote infection prevention, equip surgical and interventional procedures, and support the management of diabetes. The company partners with organizations around the world to address some of the most challenging global health issues.

Industry sector: Medical

Sector classification: Surgical & medical instruments

Deep Learning based analysis and prediction model for Becton, Dickinson and Company (BDX) stock is a 2nd Generation Non-linear Autoregressive (NAR) model based on the LSTM/GRU Recurrent Neural Network architecture.

Model is in the production pipeline since Oct. 2, 2015.

Market data for BDX model training are being downloaded from the Quandl premium datasets on a daily basis.

Model is being retrained on a regular basis.

Float 264M
P/E 23.88
Shares Outstanding 266M
% Held by Insiders 1.00%
% Held by Institutions 83.70%
EPS (last reported FY) $9.48
EPS (last reported Q) $2.48
EPS, estimated (last reported Q) $2.40
Total revenues $12 B
Net income $1 B